Axsome Therapeutics (AXSM) Misses Q4 EPS by 28c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.41), $0.28 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $24.37 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• IBM plunges 19% as memory capex squeeze derails Q2 earnings
• JPMorgan (JPM) Tops Q2 EPS by $2.15, Beats on Revenue
• Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10